<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01403519</url>
  </required_header>
  <id_info>
    <org_study_id>437-10CTIL</org_study_id>
    <nct_id>NCT01403519</nct_id>
  </id_info>
  <brief_title>Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized</brief_title>
  <official_title>Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tau pathology and tangles have been associated with cognitive dysfunction causing
      neurodegeneration. AD, the most abundant tauopathy is characterized by amyloid plaques and
      tau tangles. An abundance of tau inclusions, in the absence of amyloid deposits, defines
      Pick's disease (frontotemporal lobar degeneration), progressive supranuclear palsy (PSP),
      corticobasal degeneration (CBD) and other diseases including frontal atrophy associated with
      cognitive clinical dysfunction of frontal dysexecutive syndrome, progressive nonfluent
      aphasia and semantic dementia as recently reviewed (Gozes 2010). It is the investigators aim
      to follow other protein expression [as per recent publications (Marksteiner et al., 2011)] in
      blood and CSF samples from those tauopathies.

      Significance: Results should establish the possibility of using tau and other proteins as
      markers for early detection and disease progression in FTD, also in comparison to Alzheimer's
      disease (AD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessing biomarkers in Alzheimer's disease and frontotemporal dementia

        1. Specific Aims

           To enhance the field of biomarker recognition and facilitate preventative and
           personalized medicine we are now posing the following question, does the Israeli patient
           population present similar plasma protein profile as described before for other
           populations (Marksteiner et al., 2011).

           Studies will be carried out by RNA transcript quantification, quantitative real time
           polymerase chain reaction (blood cells and CSF) and immunochemical detection at the
           protein level (CSF and serum).

        2. Methods:

      Lymphocytes:

      Human lymphocytes are isolated from 10 ml of venous blood using the Ficoll Paque method (de
      Rock and Taylor 1977; McCauley and Hartmann, 1982), for RNA extraction and determinations we
      shall follow-up the methods described in our manuscripts (Dresner et al., 2011).

      Blood plasma and serum will be prepared as outlined in www.peoimmune.com. Protein
      quantitation will be carried out using the Tri reagent (Sigma) which allows for simultaneous
      preparation of RNA, DNA and protein and plasma immunodepletion and albumin depletion kits
      from Sigma.

      Protein quantification: this will be carried out on cellular proteins and also on plasma
      proteins by SDS-polyacrylamide gel electrophoresis, followed by western analysis.

      CSF samples will be collected through a spinal needle inserted into the L4-L5 or L3-L4
      vertebral space with the subject in the lateral decubitus position. One ml of CSF derived
      from each patient will be immediately immersed in ice, with subsequent maintenance at -70
      degrees C (or in dry ice during shipping) until the time of the assay. Half ml of each CSF
      sample will be concentrated by lyophilization in a Speed-Vac (Holten, Gydevang, Denmark) to
      about 0.1ml. CSF protein immunoblotting will be performed using a similar methodology as
      described above [and see also(Kozlovsky et al., 2004)]. Protein expression will be analyzed
      by western blots (Shiryaev et al., 2010).

      Number of patients:

      We estimate that about 30 patients with Alzheimer's disease, 20 patients with frontotemporal
      dementia and 20 controls will be included.

      Professor Aharon-Peretz will evaluate patients with suspected Alzheimer's disease and
      frontotemporal dementia and include patients at various disease stages in a stratified manner
      (mild, moderate and severe). All patients will have signed an informed consent form, as per
      Helsinki guidelines. Clinical evaluation will include: physical and neurological evaluation.
      All patients will be asked to donate 50 ml blood and selected patients will undergo lumber
      puncture. The lumber puncture will be performed with the neurological work up. Professor
      Gozes will coordinate the scientific aspect of the study.

      Study coordinators:

      Scientific: Professor Illana Gozes, PhD, The Lily and Avraham Gildor Chair for the
      Investigation of Growth Factors; Director, The Adams Super Center for Brain Studies, Tel Aviv
      University: igozes@post.tau.ac.il Clinical material: Professor Judith Aharon-Peretz, MD, Head
      of &quot;Cognitive Neurology Unit&quot; Rambam Rambam-Health Care Campus, Haifa, Israel
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Alzheimer's disease patients</arm_group_label>
    <description>Patients blood and CSF samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Blood and CSF samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FTD patients</arm_group_label>
    <description>Blood ad CSF samples</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and CSF
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We estimate that about 30 patients with Alzheimer's disease, 20 patients with
        frontotemporal dementia and 20 controls will be included.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimal cognitive impairment (MCI) and Alzheimer's disease (AD) patients, men and
             women, age 45-80 will be asked to participate in the present study.

          -  MCI will be diagnosed when on cognitive evaluation the patients will score &lt;1.5 SD on
             memory tests and will not be demented. AD will be diagnosed according to NINCDS-ADRDA
             research criteria. Patients will be stratified by age and cognitive (dementia) status.
             Disease severity for AD: mild to moderate (MMSE &gt;16) AD.

          -  Frontotemporal dementia: patients with a clinical diagnosis of frontotemporal dementia
             [behavioral variants (bv)FTD, progressive nonfluent aphasia (PNFA), or semantic
             dementia] and the related syndromes corticobasal syndrome (CBS) and progressive
             supranuclear palsy (PSP) will be included.

          -  Inclusion criteria (controls): men and women, ages 45-80, willing to participate in
             the study and donate a blood samples.

        Exclusion Criteria:

          -  (patients and controls):

               1. Subjects unable/unwilling to sign an informed consent.

               2. Patients with associated medical condition: alcoholism, immune diseases and end
                  stage medical conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Aharon-Peretz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Hospital, Haifa, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Illana Gozes, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv University, Sackler School of Medicine, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam Hospital</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judith Aharon-Peretz, M.D.</last_name>
      <phone>972-4-8542637</phone>
      <email>jaharon@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Gozes I. Tau pathology and future therapeutics. Curr Alzheimer Res. 2010 Dec;7(8):685-96. Review.</citation>
    <PMID>20678069</PMID>
  </reference>
  <reference>
    <citation>Marksteiner J, Kemmler G, Weiss EM, Knaus G, Ullrich C, Mechtcheriakov S, Oberbauer H, Auffinger S, Hinterh√∂lzl J, Hinterhuber H, Humpel C. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2011 Mar;32(3):539-40. doi: 10.1016/j.neurobiolaging.2009.03.011. Epub 2009 Apr 22.</citation>
    <PMID>19395124</PMID>
  </reference>
  <reference>
    <citation>de Rock E, Taylor N. An easy method of layering blood over Ficoll-Paque gradients. J Immunol Methods. 1977;17(3-4):373-4.</citation>
    <PMID>562380</PMID>
  </reference>
  <reference>
    <citation>McCauley I, Hartmann PE. The estimation of B lymphocytes and their subpopulations in pigs. A comparison between a method using whole blood and one using Ficoll-Paque purified mononuclear cells. J Immunol Methods. 1982;50(1):33-8.</citation>
    <PMID>6979582</PMID>
  </reference>
  <reference>
    <citation>Dresner E, Agam G, Gozes I. Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. Eur Neuropsychopharmacol. 2011 May;21(5):355-61. doi: 10.1016/j.euroneuro.2010.06.004. Epub 2010 Jul 3.</citation>
    <PMID>20598862</PMID>
  </reference>
  <reference>
    <citation>Kozlovsky N, Regenold WT, Levine J, Rapoport A, Belmaker RH, Agam G. GSK-3beta in cerebrospinal fluid of schizophrenia patients. J Neural Transm (Vienna). 2004 Aug;111(8):1093-8. Epub 2004 Apr 27.</citation>
    <PMID>15254796</PMID>
  </reference>
  <reference>
    <citation>Shiryaev N, Jouroukhin Y, Gozes I. 3R tau expression modifies behavior in transgenic mice. J Neurosci Res. 2010 Sep;88(12):2727-35. doi: 10.1002/jnr.22431.</citation>
    <PMID>20544828</PMID>
  </reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2011</study_first_submitted>
  <study_first_submitted_qc>July 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <last_update_submitted>July 26, 2011</last_update_submitted>
  <last_update_submitted_qc>July 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof' Judith Aharon-Peretz</name_title>
    <organization>Rambam Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

